{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:45:13Z","timestamp":1787168713025,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T00:00:00Z","timestamp":1574985600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T00:00:00Z","timestamp":1574985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s12012-019-09556-3","type":"journal-article","created":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T22:03:02Z","timestamp":1574978582000},"page":"321-327","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Impact of Arterial Hypertension on Doxorubicin-Based Chemotherapy-Induced Subclinical Cardiac Damage in Breast Cancer Patients"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9583-4475","authenticated-orcid":false,"given":"Domas","family":"Vaitiekus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gintare","family":"Muckiene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrone","family":"Vaitiekiene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dainora","family":"Maciuliene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dovile","family":"Vaiciuliene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grete","family":"Ambrazeviciute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liveta","family":"Sereikaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dovydas","family":"Verikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaldas","family":"Jurkevicius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elona","family":"Juozaityte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,29]]},"reference":[{"issue":"6","key":"9556_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians,68(6), 394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"Suppl 7","key":"9556_CR2","doi-asserted-by":"publisher","first-page":"vii155","DOI":"10.1093\/annonc\/mds293","volume":"23","author":"G Curigliano","year":"2012","unstructured":"Curigliano, G., Cardinale, D., Suter, T., Plataniotis, G., de Azambuja, E., Sandri, M. T., et al. (2012). Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Annals of Oncology,23(Suppl 7), vii155\u2013vii166.","journal-title":"Annals of Oncology"},{"issue":"5","key":"9556_CR3","doi-asserted-by":"publisher","first-page":"490","DOI":"10.4103\/0253-7613.190719","volume":"48","author":"K Rygiel","year":"2016","unstructured":"Rygiel, K. (2016). Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials. Indian Journal of Pharmacology,48(5), 490\u2013497.","journal-title":"Indian Journal of Pharmacology"},{"issue":"11","key":"9556_CR4","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.jash.2014.08.009","volume":"8","author":"S Szmit","year":"2014","unstructured":"Szmit, S., Jurczak, W., Zaucha, J. M., Drozd-Soko\u0142owska, J., Spycha\u0142owicz, W., Joks, M., et al. (2014). Pre-existing arterial hypertension as a risk factor for early left ventricular systolic dysfunction following (R)-CHOP chemotherapy in patients with lymphoma. Journal of the American Society of Hypertension,8(11), 791\u2013799. https:\/\/doi.org\/10.1016\/j.jash.2014.08.009.","journal-title":"Journal of the American Society of Hypertension"},{"issue":"22","key":"9556_CR5","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1200\/JCO.2007.14.9401","volume":"26","author":"L Gianni","year":"2008","unstructured":"Gianni, L., Herman, E. H., Lipshultz, S. E., Minotti, G., Sarvazyan, N., & Sawyer, D. B. (2008). Anthracycline cardiotoxicity: From bench to bedside. Journal of Clinical Oncology,26(22), 3777\u20133784. https:\/\/doi.org\/10.1200\/JCO.2007.14.9401.","journal-title":"Journal of Clinical Oncology"},{"key":"9556_CR6","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/S0040-4039(01)97723-8","volume":"13","author":"F Arcamone","year":"1969","unstructured":"Arcamone, F., Franceschi, G., Penco, S., & Selva, A. (1969). Adriamycin (14-hydroxydaunomycin), a novel antitumor antibiotic. Tetrahedron Letters,13, 1007\u20131010.","journal-title":"Tetrahedron Letters"},{"issue":"Suppl 1","key":"9556_CR7","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1517\/14740338.2011.589834","volume":"11","author":"P Menna","year":"2012","unstructured":"Menna, P., Paz, O. G., Chello, M., Covino, E., Salvatorelli, E., & Minotti, G. (2012). Anthracycline cardiotoxicity. Expert Opinion on Drug Safety,11(Suppl 1), S21\u2013S36. https:\/\/doi.org\/10.1517\/14740338.2011.589834.","journal-title":"Expert Opinion on Drug Safety"},{"issue":"2","key":"9556_CR8","doi-asserted-by":"publisher","first-page":"428","DOI":"10.5114\/aoms.2016.59270","volume":"12","author":"M Valcovici","year":"2016","unstructured":"Valcovici, M., Andrica, F., Serban, C., & Dragan, S. (2016). Cardiotoxicity of anthracycline therapy: Current perspectives. Archives of Medical Science,12(2), 428\u2013435. https:\/\/doi.org\/10.5114\/aoms.2016.59270.","journal-title":"Archives of Medical Science"},{"issue":"5","key":"9556_CR9","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","volume":"20","author":"A Seidman","year":"2002","unstructured":"Seidman, A., Hudis, C., Pierri, M. K., Shak, S., Paton, V., Ashby, M., et al. (2002). Cardiac dysfunction in the trastuzumab clinical trials experience. Journal of Clinical Oncology,20(5), 1215\u20131221.","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"9556_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/jnci\/djp440","volume":"102","author":"A Albini","year":"2010","unstructured":"Albini, A., Pennesi, G., Donatelli, F., Cammarota, R., De Flora, S., & Noonan, D. M. (2010). Cardiotoxicity of anticancer drugs: The need for cardio-oncology and cardio-oncological prevention. Journal of the National Cancer Institute,102(1), 14\u201325. https:\/\/doi.org\/10.1093\/jnci\/djp440.","journal-title":"Journal of the National Cancer Institute"},{"key":"9556_CR11","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","volume":"20","author":"A Seidman","year":"2002","unstructured":"Seidman, A., Hudis, C., Pierri, M. K., et al. (2002). Cardiac dysfunction in the trastuzumab clinical trials experience. Journal of Clinical Oncology,20, 1215\u20131221.","journal-title":"Journal of Clinical Oncology"},{"issue":"25","key":"9556_CR12","doi-asserted-by":"publisher","first-page":"3808","DOI":"10.1200\/JCO.2006.10.4976","volume":"25","author":"MC Pinder","year":"2007","unstructured":"Pinder, M. C., Duan, Z., Goodwin, J. S., Hortobagyi, G. N., & Giordano, S. H. (2007). Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. Journal of Clinical Oncology,25(25), 3808\u20133815.","journal-title":"Journal of Clinical Oncology"},{"issue":"19","key":"9556_CR13","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1200\/JCO.2007.14.1242","volume":"26","author":"DL Hershman","year":"2008","unstructured":"Hershman, D. L., McBride, R. B., Eisenberger, A., Tsai, W. Y., Grann, V. R., & Jacobson, J. S. (2008). Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin\u2019s lymphoma. Journal of Clinical Oncology,26(19), 3159\u20133165. https:\/\/doi.org\/10.1200\/JCO.2007.14.1242.","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"9556_CR14","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.acmx.2013.08.006","volume":"84","author":"J Salazar-Mendiguch\u00eda","year":"2014","unstructured":"Salazar-Mendiguch\u00eda, J., Gonz\u00e1lez-Costello, J., Roca, J., Ariza-Sol\u00e9, A., Manito, N., & Cequier, A. (2014). Anthracycline-mediated cardiomyopathy: Basic molecular knowledge for the cardiologist. Archivos de Cardiolog\u00eda de M\u00e9xico,84(3), 218\u2013223. https:\/\/doi.org\/10.1016\/j.acmx.2013.08.006.","journal-title":"Archivos de Cardiolog\u00eda de M\u00e9xico"},{"key":"9556_CR15","doi-asserted-by":"publisher","first-page":"8139861","DOI":"10.1155\/2016\/8139861","volume":"2016","author":"RK Kuriakose","year":"2016","unstructured":"Kuriakose, R. K., Kukreja, R. C., & Xi, L. (2016). Potential therapeutic strategies for hypertension-exacerbated cardiotoxicity of anticancer drugs. Oxidative Medicine and Cellular Longevity,2016, 8139861.","journal-title":"Oxidative Medicine and Cellular Longevity"},{"issue":"1","key":"9556_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3109\/08037051.2014.868629","volume":"23","author":"G Mancia","year":"2014","unstructured":"Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., & B\u00f6hm, M. (2014). 2013 ESH\/ESC practice guidelines for the management of arterial hypertension. Blood Pressure,23(1), 3\u201316. https:\/\/doi.org\/10.3109\/08037051.2014.868629.","journal-title":"Blood Pressure"},{"issue":"6","key":"9556_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s11936-014-0315-4","volume":"16","author":"S Raj","year":"2014","unstructured":"Raj, S., Franco, V. I., & Lipshultz, S. E. (2014). Anthracycline-induced cardiotoxicity: A review of pathophysiology, diagnosis, and treatment. Current Treatment Options in Cardiovascular Medicine,16(6), 315. https:\/\/doi.org\/10.1007\/s11936-014-0315-4.","journal-title":"Current Treatment Options in Cardiovascular Medicine"},{"issue":"4","key":"9556_CR18","doi-asserted-by":"publisher","first-page":"e336","DOI":"10.5301\/jbm.5000041","volume":"28","author":"D Vivenza","year":"2013","unstructured":"Vivenza, D., Feola, M., Garrone, O., Monteverde, M., Merlano, M., & Lo, Nigro C. (2013). Role of the renin-angiotensin-aldosterone system and the glutathione S-transferase Mu, Pi and Theta gene polymorphisms in cardiotoxicity after anthracycline chemotherapy for breast carcinoma. International Journal of Biological Markers,28(4), e336\u2013e347. https:\/\/doi.org\/10.5301\/jbm.5000041.","journal-title":"International Journal of Biological Markers"},{"issue":"Suppl 5","key":"9556_CR19","doi-asserted-by":"publisher","first-page":"v9","DOI":"10.1093\/annonc\/mdq159","volume":"21","author":"S Aebi","year":"2010","unstructured":"Aebi, S., Davidson, T., Gruber, G., Castiglione, M., & ESMO Guidelines Working Group. (2010). Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology,21(Suppl 5), v9\u2013v14. https:\/\/doi.org\/10.1093\/annonc\/mdq159.","journal-title":"Annals of Oncology"},{"issue":"2","key":"9556_CR20","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s12012-007-0015-3","volume":"7","author":"H Cort\u00e9s-Funes","year":"2007","unstructured":"Cort\u00e9s-Funes, H., & Coronado, C. (2007). Role of anthracyclines in the era of targeted therapy. Cardiovascular Toxicology,7(2), 56\u201360.","journal-title":"Cardiovascular Toxicology"},{"issue":"11","key":"9556_CR21","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/cncr.11407","volume":"97","author":"SM Swain","year":"2003","unstructured":"Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003). Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of threetrials. Cancer,97(11), 2869\u20132879.","journal-title":"Cancer"},{"issue":"1","key":"9556_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/eurjhf\/hfq213","volume":"13","author":"T Eschenhagen","year":"2011","unstructured":"Eschenhagen, T., Force, T., Ewer, M. S., de Keulenaer, G. W., Suter, T. M., Anker, S. D., et al. (2011). Cardiovascular side effects of cancer therapies: A position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure,13(1), 1\u201310. https:\/\/doi.org\/10.1093\/eurjhf\/hfq213.","journal-title":"European Journal of Heart Failure"},{"issue":"5","key":"9556_CR23","doi-asserted-by":"publisher","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","volume":"91","author":"DD Von Hoff","year":"1979","unstructured":"Von Hoff, D. D., Layard, M. W., Basa, P., Davis, H. L., Jr., Von Hoff, A. L., Rozencweig, M., et al. (1979). Risk factors for doxorubicin-induced congestive heart failure. Annals of Internal Medicine,91(5), 710\u2013717.","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"9556_CR24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.taap.2013.08.012","volume":"273","author":"LC Sharkey","year":"2013","unstructured":"Sharkey, L. C., Radin, M. J., Heller, L., Rogers, L. K., Tobias, A., Matise, I., et al. (2013). Differential cardiotoxicity in response to chronic doxorubicin treatment in male spontaneous hypertension-heart failure (SHHF), spontaneously hypertensive (SHR), and Wistar Kyoto (WKY) rats. Toxicology and Applied Pharmacology,273(1), 47\u201357. https:\/\/doi.org\/10.1016\/j.taap.2013.08.012.","journal-title":"Toxicology and Applied Pharmacology"},{"issue":"1","key":"9556_CR25","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1093\/toxsci\/kfp092","volume":"110","author":"MS Hazari","year":"2009","unstructured":"Hazari, M. S., Haykal-Coates, N., Winsett, D. W., Costa, D. L., & Farraj, A. K. (2009). Continuous electrocardiogram reveals differences in the short-term cardiotoxic response of Wistar-Kyoto and spontaneously hypertensive rats to doxorubicin. Toxicological Sciences,110(1), 224\u2013234. https:\/\/doi.org\/10.1093\/toxsci\/kfp092.","journal-title":"Toxicological Sciences"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-019-09556-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12012-019-09556-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-019-09556-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T19:36:58Z","timestamp":1606505818000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12012-019-09556-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,29]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["9556"],"URL":"https:\/\/doi.org\/10.1007\/s12012-019-09556-3","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,29]]},"assertion":[{"value":"29 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Permission from the Kaunas regional Bioethics Committee was obtained. (No.: BEC MF 361). All patients gave written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}}]}}